Jennifer Dent

Jennifer Dent is the President & CEO of BIO Ventures for Global Health (BVGH). She joined BVGH in 2011 and took over leadership of the organization in 2012. She has facilitated partnerships across the private, government, and public sectors involving more than 50 countries. Ms. Dent leverages her international industry experience to tackle tough global health challenges with market-driven approaches focusing on sustainability, scalability, and most importantly, priorities and needs as determined by each African or low- and middle-income country partner. Prior to joining BVGH, Ms. Dent worked for Hoffmann-La Roche as an Alliance Director in South San Francisco at the Genentech site. She has 20+ years of broad-based pharmaceutical and biotechnology experience, including negotiation and structuring of deals and management of global discovery and commercial alliances. Ms. Dent began her career as a sales representative in Canada working in a variety of positions for Parke Davis/Pfizer and Genentech. Following the acquisition of Genentech Canada by Roche, Ms. Dent held a number of senior management positions in marketing, life cycle management, global product strategy, business development, and alliance management at Roche and Genentech in Canada, Switzerland, New Jersey, and South San Francisco. Ms. Dent co-founded Sound Biotechnology, and prior to that, served as Vice President, Business Development, Marketing, and Sales at CombiMatrix Corporation in Washington State. Ms. Dent received her MBA from the Richard Ivey School of Business, Western University and her BSc from Western University in Canada.

Ms. Dent has moderated numerous panels, including sessions at the 2014-2018 BIO International Conventions."
Speaking In
9:00 AM - 10:00 AM
Thursday, June 8
During the recent U.S.-Africa Leaders Summit in December 2022, First Lady Dr. Jill Biden recognized…